IFIH1 TT SNP and SLE Risk
The IFIH1 rs1990760 TT genotype is associated with increased susceptibility to systemic lupus erythematosus, but current clinical practice guidelines do not recommend routine genetic testing for IFIH1 polymorphisms in SLE diagnosis or management 1, 2.
Evidence for Genetic Association
The IFIH1 rs1990760 polymorphism shows a modest but consistent association with SLE risk across multiple populations:
- The T allele increases SLE susceptibility with an odds ratio of approximately 1.20-1.36 across studies 3, 4, 5
- Meta-analysis confirms the rs1990760 association with SLE onset (P < 0.05) 4
- The TT genotype specifically associates with anti-dsDNA antibody positivity 3, 6
Mechanistic Insights
The risk variant functions through enhanced type I interferon signaling:
- TT genotype carriers demonstrate increased sensitivity to IFN-α despite having paradoxically lower serum IFN-α levels in anti-dsDNA-positive patients 6
- TT carriers show lower serum IL-18 (P < 0.001) and granzyme B levels (P < 0.001) compared to CC/CT carriers 3
- The variant increases basal interferon-stimulated gene expression and MDA5 ATPase activity 7
Clinical Recommendations
Standard SLE management should be followed regardless of IFIH1 genotype, as guidelines prioritize clinical phenotype over genetic risk factors 1, 2:
Core Management Principles
Disease monitoring using validated activity indices at each visit, with organ damage assessment annually 8
Baseline autoantibody panel: ANA, anti-dsDNA, anti-Ro, anti-La, anti-RNP, anti-Sm, antiphospholipid antibodies, C3, C4 8
Universal antimalarial therapy for all SLE patients unless contraindicated 1
Glucocorticoid minimization: Use lowest effective dose for shortest duration 1, 2
Specific Considerations for IFIH1 TT Carriers
While not guideline-based, the research suggests these patients may warrant:
- Enhanced monitoring for anti-dsDNA antibodies given the strong association 3, 6
- Awareness of altered interferon signaling when considering biologic therapies targeting type I IFN pathways
- Recognition that lower IL-18 levels may not reflect reduced disease activity in these patients 3
What NOT to Do
Do not order IFIH1 genotyping for:
- Diagnostic purposes (not part of classification criteria)
- Risk stratification (effect size too modest to change management)
- Treatment selection (no genotype-specific therapies exist)
Important Caveats
The IFIH1 association demonstrates ethnic variability: stronger effects observed in Chinese populations 3, 5 compared to Brazilian cohorts 4. The TT genotype confers only modest increased risk (OR ~1.3-1.4), far less impactful than clinical factors like disease activity, organ involvement, and treatment adherence 1.
Juvenile-onset SLE shows stronger IFIH1 associations with early disease onset (<12 years) and high disease activity (SLEDAI-2K >10) 9, but this remains a research finding without clinical application.
The genetic effect is independent of STAT4 genotype, suggesting additive interferon pathway dysregulation 6, but combined genetic risk scoring is not clinically validated.